Citations

Clear

4510 citation(s) found for "Oh, Scott".

NOTQ-04 NEUROCOGNITIVE OUTCOMES IN PATIENTS WITH BRAIN METASTASES: A SYSTEMATIC REVIEW OF PAST FINDINGS AND FUTURE DIRECTIONS
Dargham, Tarek Bou, Batich, Kristen, Gehring, Karin , Dietrich, Jorg, Mullikin, Trey, Hattangadi-Gluth, Jona, Brown, Paul D, Mehta, Minesh, Vaios, Eugene , Dargham, Tarek Bou , Winter, Sebastian Friedrich , Parsons, Michael , Dietrich, Jörg , Reitman, Zachary J. , Floyd, Scott , Kirkpatrick, John P. , Sperduto, Paul W. , Hattangadi‐Gluth, Jona A. , Shih, Helen A. , Sulman, Erik P. , Peters, Katherine B.

Mayo Clinic

Neuro-Oncology Advances | August 7, 2026 | Volume: 8 | Issue: Supplement_6 | Pages: No page available

10.1093/noajnl/vdag161.053 Get It

Abstract Background Multi-modality therapy has improved survival for many patients with brain metastases. However, neurocognitive sequelae remain a challenge. While advances in radiotherapy have reduced toxicity, the potential interaction with targeted therapy and immunotherapy and the consequent impact on neurocognitive outcomes remain poorly defined. We appraised the current evidence on neurocognitive outcomes in the era of modern combined-modality therapy. Methods This systematic review adhered to PRISMA guidelines and included clinical trials reporting neurocognitive outcomes in patients with brain metastases receiving radiotherapy ± concurrent systemic therapies. Studies published through December 31, 2024 were identified through PubMed/Medline, EMBASE, and Web of Science using pre-defined MeSH term-based search strings. Results 39 studies from 1997-2024 involving 6,617 patients met inclusion criteria (n = 27 whole-brain radiotherapy [WBRT]; n = 12 radiosurgery), including six studies evaluating combined-modality therapy in 1,161 patients. Baseline cognitive evaluation was performed inconsistently, but neurocognitive deficits were frequently observed prior to treatment. Most randomized trials reported improved cognitive outcomes and quality of life with advanced radiotherapy techniques (e.g., hippocampal avoidance, radiosurgery) vs WBRT. Among 20 randomized trials comparing radiotherapy with or without a concurrent investigational systemic therapy, only four included neurocognitive assessments. There was no evidence of cognitive sequelae with combined-modality therapy, though evaluable trials were limited due to inconsistent reporting of neurocognitive functioning. Conclusion As survival improves in patients with brain metastases, preserved cognition is an important outcome measure. The lack of neurocognitive endpoints in pivotal brain metastasis trials represents a critical evidence gap. The interaction between radiotherapy and novel systemic therapies, and their combined effects on neurocognition, remain unknown. To address this, we recommend 1) integrating sensitive, pragmatic, and tailored neurocognitive assessments into oncology trials to quantify additive toxicity, 2) early and systematically incorporating neuropsychology into care pathways, 3) expanding radiation dose-sparing and radioprotective strategies, and 4) evaluating the utility of cognitive rehabilitation programs.
TNK1 is a targetable JAK-independent driver of STAT signaling and inflammation
Scott, Samuel, Vaughan, Alec , Egbert, Christina M., Chan, Tsz‐Yin, Bustos, Yaphet , Ashworth, Spencer, Truman, Jacob M., Moreno, Angela Per, Tsang, Tsz‐Ming, Jayatunge, Dasun N., Yang, Jingshu, Nelson, Paige, Al-Sudani, Fatima, Tarara, Madelyn, Kohler, Emmalee, Mendiola, Nelson E. Pereira, Soderblom, Erik J. , Kolasangiani, Reza , Dobish, Kasidy K., Knobel, Beate, Buckley, Shannon M., Bidone, Tamara C., Morawe, Mareen , Armacki, Milena , Andersen, Joshua L., Stewart, Paul A , Smoot, Rory L , López-Palacios, Tania P. , Madhusanka, Deshan , Scott, Samuel M., Egbert, Christina M. , Truman, Jacob, Jayatunge, Dasun , Nelson, Paige, Stubben, Chris , Buckley, Shannon M. , Bidone, Tamara C. , Smoot, Rory L. , Uchida, Amiko M. , Andersen, Joshua L.

Mayo Clinic

Genes & Development | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/gad.353368.125 | PMID 42547268 Get It

Deregulated inflammatory signaling via STAT family transcription factors, particularly STAT1, underlies a variety of immune-related diseases, including inflammatory bowel disease. Whereas activation of STATs by JAKs via canonical receptor-driven JAK–STAT signaling is well understood, little is known about JAK-independent mechanisms of STAT activation. Here, we identify the understudied nonreceptor tyrosine kinase TNK1 as a therapeutically targetable, JAK-independent activator of STAT signaling. Using a multiomics approach, we mapped a network of TNK1 substrates associated with protein condensates and proinflammatory signaling, including STAT1. We found that TNK1, but not its sister kinase ACK1, directly phosphorylates STATs at well described STAT-activating JAK sites. In cells, TNK1-mediated STAT1 phosphorylation and activation occurs independently of JAKs. Imaging and interactomics data suggest that TNK1 interacts with STAT1 in cytosolic condensates, which likely compartmentalize TNK1-substrate interactions. We show that an intrinsically disordered proline-rich region in TNK1, which includes a 14-3-3 docking phosphorylation site, is required for the formation of kinase-active TNK1 condensates and STAT1 phosphorylation. Mutations within the proline-rich region that eliminate 14-3-3 binding increase formation of TNK1 condensates, suggesting a model in which 14-3-3 acts as a clamp that constrains the flexible PRR to inhibit condensate formation and STAT1 activation. Finally, we show that TNK1 is a targetable driver of STAT1-mediated inflammation in the gut as inhibition of TNK1 reduces active STAT1 in the colon and ameliorates colitis symptoms in mice.
Effect of time to palliative epilepsy surgery on outcomes
Crutcher, Robert M. , Horvat, David , Caraway, Avery R. , Arredondo, Kristen H. , Abel, Taylor J. , Agarwal, Nitin , Alexander, Allyson , Armstrong, Dallas , Auguste, Kurtis I. , Bernardo, Danilo , Bolton, Jeffrey , Bonda, David , Depositario‐Cabacar, Dewi F. , Groves, Aran, Hauptman, Jason S. , Knox, Andrew , Lin, Jenny, McGoldrick, Patricia E. , Miller, D. , Ostendorf, Adam P. , Pichon, Pilar, Reddy, Shilpa B. , Samanta, Debopam , Singh, Rani K. , Wagner, Janelle L. , Galán, Fernando , Perry, Μ. Scott , Ciliberto, Michael A. , Horvat, David E , Alexander, Allyson L , Armstrong, Dallas Michael , Depositario Cabacar, Dewi Frances , Eschbach, Krista , Gaillard, William D , Hauptman, Jason , Javarayee, Pradeep K , Karakas, Cemal , Knox, Andrew T , McGoldrick, Patricia E , Miller, Derryl J , Novotny, Edward J , Ostendorf, Adam P , Pichon, Pilar D , Reddy, Shilpa B , Samanta, Debopam , Singh, Rani K , Wagner, Janelle , Wolf, Steven , Wong-Kisiel, Lily C. , Galan, Fernando N , Perry, Michael Scott , Ciliberto, Michael A , Auguste, Kurtis I , Arredondo, Kristen H , Abel, Taylor J , Agarwal, Nitin , Bernardo, Danilo , Crutcher, Robert , Bonda, David , Depositario‐Cabacar, Dewi, Eschbach, Krista , Gaillard, William D. , Javarayee, Pradeep , Karakas, Cemal , Novotny, Edward J. , Wolf, Steven M. , Wong‐Kisiel, Lily C.

Mayo Clinic

Epilepsia | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70379 | PMID 42545811 Get It

Abstract Objective Epilepsy duration is a modifiable risk factor in the outcome of definitive epilepsy surgery; however, an analogous effect in palliative procedures has not been shown. We reviewed the Pediatric Epilepsy Surgery Database data for an association between epilepsy duration and seizure reduction in palliative procedures. Methods Patients enrolled between January 2018 and April 2025 who underwent their first epilepsy surgery with palliative intent with 6 months of follow‐up were included. Procedures included neuromodulation, corpus callosotomy, hemispherotomy, lesionectomy, and lobectomy where surgical intent was not seizure freedom. Outcomes of seizure freedom, 90% seizure reduction, and 50% seizure reduction were considered at 6–12 months and >12 months from surgery. Duration from epilepsy onset to surgery was compared for patients above and below each outcome threshold at each time point. Logistic regression analysis for the association between epilepsy duration and seizure reduction adjusted for potential confounders including procedure type, etiology, and other clinical factors. Logistic regression analysis was performed on the overall cohort and subgroups of patients with each procedure. Results A total of 588 patients were included. Initial univariate analysis suggested that epilepsy duration at time of surgery was significantly associated with seizure freedom and 90% seizure reduction at both 6–12 months and >12 months. After adjusting for confounders, only seizure freedom at >12 months was significantly associated with duration of epilepsy. When individual procedures were considered, only lobectomy was sensitive to duration of epilepsy in multivariate analysis, with significant impacts on >50% and >90% seizure reduction at >12 months. Lesional epilepsy predicted seizure freedom at >12 months. Neuromodulation and corpus callosotomy were less likely to achieve seizure reduction than other procedures. Significance We did not find an association between early epilepsy surgery and seizure reduction. This reflects the heterogeneity of our population, including different types of surgical procedures and lesional and nonlesional epilepsies.
WSB1-Mediated PSMA Ubiquitination Promotes Enzalutamide-Induced Neuroendocrine-like Transition in Patient-Derived Prostate Cancer Spheroids
Jung, Dawa, Kendi, A. Tuba , Woodrum, David A. , In, Myung‐Ho , Bilgin, Gokce Belge , Johnson, Derek R. , Kim, Eun-Joo, Chung, Jin Ook , Park, Seon-Young , Curran, Geoffry L., Lowe, Val J. , Lee, Seung Baek , Kendi, A Tuba , Adamo, Daniel A. , In, Myung-Ho , Belge Bilgin, Gokce , Johnson, Derek R , Horn, Ian M, Lowe, Val J , Lee, Seung Baek , Thompson, Scott M. , Horn, Ian M. , Curran, Geoffry L.

Mayo Clinic

International Journal of Molecular Sciences | August 3, 2026 | Volume: 27 | Issue: 15 | Pages: 6899

10.3390/ijms27156899 | PMID 42589556 Get It

Long-established prostate cancer cell lines provide limited insight into how contemporary early prostate cancer evolves into drug-resistant and neuroendocrine-like refractory disease. Patient-derived three-dimensional (3D) ex vivo models may better preserve this transition. Here, we found that 8 of 10 magnetic resonance imaging-guided biopsy specimens from patients with early-stage prostate cancer generated sustained 3D tumor spheroid cultures. After 12 weeks of enzalutamide selection, only one patient-derived culture acquired a resistant phenotype with treatment-emergent neuroendocrine prostate cancer (t-NEPC)-like features, including increased chromogranin A (CgA) and synaptophysin (SYP); reduced androgen receptor (AR), prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA); and conversion from compact spheroids into irregular resistant aggregates. During this transition, WD repeat and SOCS box-containing protein 1 (WSB1) increased, whereas PSMA progressively decreased. WSB1 silencing restored PSMA, AR, and PSA expression and reduced neuroendocrine-associated features. A similar WSB1 dependency was observed in enzalutamide-resistant LNCaP cells, the castration-resistant prostate cancer model 22Rv1, and the neuroendocrine/small-cell prostate cancer model NCI-H660. Mechanistically, WSB1 functioned as a SOCS box-dependent E3 ubiquitin ligase adaptor that promoted PSMA ubiquitination and degradation. SOCS box deletion or T380A mutation impaired this process, while Aurora kinase A (AURKA) inhibition reduced WSB1-dependent PSMA ubiquitination. WSB1 depletion, AURKA inhibition with alisertib, and combined AURKA inhibition with EZH2 suppression reduced resistant aggregate growth and increased apoptosis-associated markers in patient-derived enzalutamide-resistant neuroendocrine-like spheroids and related models. These findings nominate the AURKA–WSB1–PSMA axis as a therapeutic vulnerability in refractory prostate cancer.
Continued concomitant antibiotic or immunosuppression therapies reduce the risk of pouchitis among patients with ileal pouch-anal anastomosis and primary sclerosing cholangitis
Haydek, John P. , Santiago, Priscila , Powers, Joseph Carter , Ruplall, Latchmin, Richardson, Hoang Anh, Causey, Erin, Elhawary, Mohamed, Karl, Taylor , Tfayli, Rami , Hashash, Jana G. , Qazi, Taha , Horst, Sara , Long, Millie D. , Raffals, Laura E. , Chang, Shannon , Horst, Sara , Scott, Frank I , Long, Millie D , Raffals, Laura , Barnes, Edward L , Hashash, Jana G , Haydek, John , Karl, Taylor A. , Chang, Sam S. , Scott, Frank I. , Barnes, Edward L.

Mayo Clinic

Crohn’s & Colitis 360 | August 3, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1093/crocol/otag091 | PMID 42598726 Get It

Abstract Background Complications such as intermittent pouchitis (IP) and chronic inflammatory disorders of the pouch (CP) are common after ileal pouch-anal anastomosis (IPAA), particularly among patients with both ulcerative colitis and primary sclerosing cholangitis (PSC). There are no standardized approaches for prophylaxis against these complications for patients with PSC undergoing IPAA. We compared outcomes among patients with PSC and IPAA who received antibiotic or immunosuppressive therapies to those who did not. Methods We designed a retrospective cohort study that included patients with ulcerative colitis and PSC from 7 tertiary care centers that underwent IPAA between 1994 and 2023. Patients were categorized on whether they received medications following IPAA that may provide primary prophylactic benefit, such as antibiotics, probiotics, immunomodulators, or biologic medications; and the proportion of patients developing IP and CP was evaluated. Results A total of 172 patients were included in the cohort, and 13 (7.6%) patients received antibiotics or immunosuppressant medications. Antibiotics and probiotics were the most common therapy (5 patients, 2.9%), followed by biologics, small-molecule inhibitors, immunomodulators, or mesalamine (all 1 patient, 0.6%). Compared to patients not receiving antibiotics or immunosuppression, patients receiving antibiotics or immunosuppression were significantly less likely to develop IP (69.2% vs 91.2%; P = .03; odds ratio 0.22; 95% CI, 0.06-0.80) and CP (23.1% vs 56.0%, P = 0.04; OR 0.24, 95% CI, 0.06-0.89). Conclusions In this retrospective cohort of patients with ulcerative colitis and PSC undergoing IPAA, usage of concomitant antibiotics or immunosuppression was low. However, use of concomitant antibiotics or immunosuppression may decrease the burden of inflammatory conditions of the pouch in these high-risk patients.
Comparison of Factors Associated With 30‐Day and 90‐Day Readmission Among a Global Cohort of Patients Hospitalised With Cirrhosis
Haktanıyan, Büşra, Choudhury, Ashok , Wong, Florence , Kamath, Patrick S. , Topazian, Mark , Hayes, P C, Álvares‐da‐Silva, Mário Reis , Torre, Aldo , Silvey, Scott, Bajaj, Jasmohan S. , Investigators, CLEARED, Barutçu, Sezgin , Fisseha, Henok , Idilman, Ramazan , Haktaniyan, Busra , Chaudhary, Ashok , Wong, Florence , Kamath, Patrick S , Xie, Qing , Topazian, Mark D , Alvares-da-Silva, Mario Reis , Torre, Aldo , George, Jacob , Seto, Wai-Kay , BUSH, BRIAN J. , Thacker, Leroy R , Bajaj, Jasmohan S , Fisseha, Henok , Idılman, Ramazan , George, Jacob , Seto, Wai‐Kay , Silvey, Scott , Thacker, Leroy R.

Mayo Clinic

Liver International | July 29, 2026 | Volume: 46 | Issue: 9 | Pages: No page available

10.1111/liv.70804 | PMID 42522657 Get It

ABSTRACT Background and Aims It remains unclear whether different factors influence 30‐ and 90‐day readmission rates. We identified predictors of 90‐day mortality in a global cohort of hospitalised patients with cirrhosis. Methods Variables associated with 30‐ and 90‐day post‐discharge readmission, liver transplantation (LT), and mortality were compared in prospectively enrolled, non‐electively hospitalised adult patients with cirrhosis. Results We enrolled 4208 patients from 125 centres across 37 countries. Alcohol‐related liver disease was the most common aetiology of cirrhosis (40%), followed by hepatitis B virus infection (21%); 47% were readmitted, 8% received liver transplantation (LT), and 23% died within 90 days post‐discharge. In multivariable analysis, country income was significantly associated with both 30‐ and 90‐day readmission rates, the receipt of LT, and mortality within 30 and 90 days post‐discharge (all p ‐values < 0.001). Independent predictors of higher rates of 30‐ and 90‐day readmissions, respectively, were disease severity ( p < 0.001, p = 0.003), prior ascites ( p = 0.025, p = 0.016), prior hospitalisation ( p < 0.001), hyponatremia ( p < 0.001, p = 0.008), and in‐hospital vasopressor use ( p = 0.002, p = 0.011). Prior variceal bleeding independently predicted higher 90‐day readmission rates, whereas age, disease severity, mechanical ventilation, and in‐hospital vasopressor use (all, p < 0.001) increased odds of 30‐ and 90‐day post‐discharge death. Additionally, admission ( p = 0.011) and nosocomial ( p = 0.022) infections increased the odds of 90‐day post‐discharge death. Conclusion In a global cohort of hospitalised patients with cirrhosis, patients in high‐income countries exhibited the highest rates of 30‐ and 90‐day readmission, alongside lower mortality rates and a higher incidence of LT. Variables that predict 30‐day readmission also predicted 90‐day readmission. Understanding these disparities is essential for achieving health equity.
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004
Wierda, William G. , Dorritie, Kathleen , Gauthier, Jordan , Nath, Rajneesh, Kipps, Thomas J. , Riedell, Peter A. , Eradat, Herbert A., Kharfan‐Dabaja, Mohamed A. , Shah, Nirav N. , Solomon, Scott R., Stephens, Deborah M., Ermann, Daniel A., Arnason, Jon , Deol, Abhinav , Feldman, Tatyana , Ghosh, Monalisa , Tuazon, Sherilyn A., Perna, Serena K., Ou, San-San, Ananthakrishnan, Revathi , Rane, Neha, Papp, Eniko, Ansari, Sahar , Thompson, Ethan G., Okal, Abood, Peiser, Leanne, Chen, Yizhe , Sengupta, Sanhita , Wang, Jixian , Wierda, William G. , Dorritie, Kathleen , Kenderian, Saad S. , Kharfan-Dabaja, Mohamed A , Shah, Nirav N , Deol, Abhinav , Ma, Shuo , Schuster, Stephen J , Gergis, Usama , Vose, Julie , Soumerai, Jacob D , Besien, Koen van , Chen, Yizhe , Sengupta, Sanhita , Ray, Pradipta Ranjan , Siddiqi, Tanya , Kipps, Thomas J , Riedell, Peter A , Nath, Rajneesh , Eradat, Herbert, Stephens, Deborah M. , Andreadis, Charalambos Babis , Ma, Shuo , Schuster, Stephen J. , Vose, Julie M. , Soumerai, Jacob D. , Tuazon, Sherilyn A. , Perna, Serena , Ou, San‐San , Papp, Eniko , Ansari, Sahar, Siddiqi, Tanya

Mayo Clinic

Blood Journal | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033565 | PMID 42520199 Get It

Patients in the liso-cel plus ibrutinib cohort of the phase 1/2, open-label TRANSCEND CLL 004 study had relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and received liso-cel (50×106 [dose level (DL)1] or 100×106 [DL2] chimeric antigen receptor-positive T cells) with concurrent ibrutinib from enrollment through 90 days after liso-cel infusion or longer per investigator discretion. Primary end point was complete response/remission (CR)/CR with incomplete marrow recovery (CRi) by investigator assessment. Among 56 patients who received ibrutinib plus liso-cel (DL1, n=5; DL2, n=51), median (range) age was 64.5 years (44‒77), 98% had high-risk cytogenetics, 55% had progression on Bruton tyrosine kinase inhibitor and venetoclax failure, and median (range) number of prior therapies was 5 (1‒13). Median (range) follow-up was 24.8 months (3.1‒51.8). At DL2, CR/CRi rate was 45% (95% confidence interval [CI], 31‒60) and overall response rate was 86% (95% CI, 74‒94). Median (95% CI) duration of response was not reached (NR; 28.7‒NR) for patients with CR/CRi and 41.4 months (23.3‒NR) for all responders. Median (95% CI) progression-free survival was 31.4 months (20.1‒NR). In DL1+DL2, most common grade ≥3 treatment-emergent adverse events (TEAE) were neutropenia (52%) and anemia (41%). Cytokine release syndrome was reported in 80% of patients (grade 3, 4%; no grade 4/5), and neurological events in 41% (grade 3/4, 11%; no grade 5). Ibrutinib-related TEAEs were reported in 68% of patients (grade 3/4, 43%; no grade 5). Liso-cel plus ibrutinib demonstrated notable efficacy in patients with relapsed/refractory CLL/SLL with predictable and manageable safety. Clinicaltrials.gov: NCT03331198; NCT03435796.
MAIT17 Cells and IL-17-Driven iBALT Formation Protect Against Pulmonary Tularemia 2267799
Okoye, Donald, Wu, Lan, Kaer, Luc Van, Algood, Holly, Joyce, Sebastian , Kumar, Amrendra , Okoye, Gosife Donald , Kaer, Luc Van , Algood, Holly M. Scott

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.1185 Get It

Abstract Introduction Here we demonstrate that respiratory infection with Francisella tularensis induces the formation of induced bronchus-associated lymphoid tissue (iBALT) as a protective mechanism against pulmonary tularemia-like disease in mice. While semi-invariant natural killer T (NKT) cells and mucosal-associated invariant T (MAIT) cells are abundant at the lung mucosa, their roles in infectious diseases remain poorly understood. Pulmonary tularemia, the most severe form of tularemia, arises from respiratory infection with F. tularensis. Using C57BL/6 mice infected with the live vaccine strain (LVS) of F. tularensis to model tularemia-like disease, we previously showed that NKT cells exacerbate disease, as NKT-deficient CD1d⁻/⁻ mice were protected. Notably, protected CD1d⁻/⁻ mice developed iBALT structures in the lungs, which were absent in C57BL/6 mice. Methods Molecular immunology methods. Results Respiratory LVS infection in CD1d⁻/⁻ mice induced a robust expansion of IL-17-producing MAIT17 cells and a decrease in regulatory T cells in the lungs compared to C57BL/6 mice. Single-cell RNA sequencing revealed a gene signature in MAIT cells linked to factors that drive iBALT formation. Supporting this notion, adoptive transfer of LVS-activated lung MAIT cells from infected CD1d⁻/⁻ mice conferred protection against tularemia-like disease in RAG2⁻/⁻ recipients, while splenic MAIT cells did not despite the fact that both populations homed to the lungs after transfer. Lung-derived MAIT cells were enriched in IL-17-producing MAIT17 cells, whereas splenic MAIT cells predominantly consisted of interferon-gamma-producing MAIT1 cells. Last, IL-17 was identified as critical for iBALT development during respiratory LVS infection in CD1d⁻/⁻ mice. Conclusion In summary, our findings establish MAIT cells as central mediators of IL-17-dependent protection against pulmonary tularemia-like disease and underscore the potential protective role of iBALT in disease resistance. Funding Source NIH AI137082, VA Merit BX001610, VA SRCS BX004595 Topic Categories Innate Immune Responses and Host Defense: Cellular Mechanisms (INC)
Siglec-9 is a functional inhibitory receptor for B7-H3 that regulates anti-tumor immunity 2260091
Medlyn, Michael, Shapiro, Michael, Kimball, Brooke, Huynh, Truc, Peterson, Kevin, Crotts, Sydney, Zastrow, Alexi, Lucien, Fabrice, Kaufmann, Scott, Kenderian, Saad, Billadeau, Daniel, Shapiro, Virginia, Chen, Yin, Medlyn, Michael J. , Shapiro, Michael, Kimball, Brooke , Huynh, Truc , Crotts, Sydney B. , Zastrow, Alexi, Lucien, Fabrice , Kenderian, Saad, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.853 Get It

Abstract Introduction Checkpoint blockade revolutionized cancer therapy. However, only a small proportion of cancers respond to checkpoint blockade. B7-H3 is a member of the B7 superfamily, which includes both co-inhibitory and co-stimulatory receptors. B7-H3 is upregulated by many tumors which is generally associated with a worse prognosis. However, the exact mechanism by which B7-H3 suppresses the immune response remains elusive. Methods We transfected human HEK293T cells and assessed the binding to recombinant Siglecs via flow cytometry. We generated monoclonal antibody F7 against human B7-H3 and tested its blocking function using B7-H3 transfected HEK293T cells. We examined the extent of degranulation and NK cell-mediated killing on B7-H3 expressing HEK293T cells in vitro, as well as the CART19 cells mediated killing in relapse model of B7-H3 expressing CD19+ leukemia Nalm6 cells NSG mice. Results We demonstrated that sialylated B7-H3 binds to the inhibitory receptor Siglec-9 on immune cells but not to the related protein Siglec-7. A high affinity monoclonal antibody (mAb) F7 against B7-H3 blocks Siglec-9 binding. Functionally, F7 enhances NK cell killing of B7-H3 expressing target cells in vitro. F7 also dramatically enhances CART19 mediated killing of B7-H3 expressing Nalm6 cells in a relapse model in NSG mice in vivo. Conclusion We have now shown for the first time that B7-H3 binds to the inhibitory receptor Siglec-9 and generated a novel monoclonal antibody F7 that target a unique sequence in B7-H3 as compared to other monoclonal antibodies being examined for clinical efficacy. F7 can promote NK cell killing of B7-H3 expressing target cells in vitro and synergize with CART19 to enhance killing of B7-H3 expressing tumor cells in vivo. As B7-H3 is overexpressed in many human cancers, this work is critical toward understanding how B7-H3 mediates immune evasion through Siglec-9 for enhancing anti-tumor immunity. Funding Source R01CA243545-01A1 Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Local disease control in patients with Erdheim–Chester disease treated with external beam radiation therapy
Shah, Meera , Tobin, W. Oliver , Goyal, Gaurav , Bennani, N. Nora , Kessel, Adam C , Burlile, Jessica F. , Freschette, Kelsey, Tobin, W Oliver , Goyal, Guarav , Shah, Mithun V , Bennani, N Nora , Rouse, Rachelle L, Lester, Scott C. , Abeykoon, Jithma P , Go, Ronald S , Breen, Will , Freschette, Kelsey, Rouse, Rachelle, Abeykoon, Jithma P. , Go, Ronald S. , Breen, William G.

Mayo Clinic

British Journal of Haematology | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70698 | PMID 42517545 Get It